PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug. GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m. AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition. Merck acquires oncology spinout Modifi Biosciences in deal worth $1.3bn.
Moderna shares positive phase 3 results for mRNA influenza …
Sep 15, 2023 · Moderna has shared positive results from a late-stage trial of its influenza vaccine, with mRNA-1010 shown to generate a stronger immune response against all four World Health Organization (WHO)-recommended flu strains compared to GSK’s Fluarix. Improved immunogenicity was observed across age groups, including older adults, and the company ...
Regulatory - PMLiVE
WHO announces priority endemic pathogens for urgent vaccine development; UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance
Merck’s adult-specific pneumococcal vaccine Capvaxive ... - PMLiVE
Jun 19, 2024 · Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) for its adult-specific 21-valent pneumococcal conjugate vaccine. Capvaxive is now authorised to prevent invasive pneumococcal disease and pneumococcal pneumonia in individuals aged 18 years and older. Diseases caused by ...
PME - Articles - Pharmaceutical Market Europe
Sep 11, 2024 · PME - Articles. TL STRADOO - Digital biomarkers: reinventing patient monitoring and care. 11 September 2024 Communique - Marketing & Comms. Read More. GLOBAL HEALTH - Causes That Count, Health’ report – key issues affecting global health. 11 September 2024 Communique - Marketing & Comms. Read More.
Celgene gets US green light for blockbuster candidate Pomalyst
Feb 11, 2013 · Celgene has been given the go-ahead by the US FDA to market Pomalyst, a new drug for multiple myeloma that has been tipped for $1bn-$1.5bn in annual sales.
PME - Home
A listing of the top 40 creative agencies working on advertising, branding, creative and design projects in the UK healthcare sector. PME – Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to ...
2023 PM Society Awards – winners announced - PMLiVE
2023 PM Society Awards – winners announced. The PM Society’s 37th annual awards was held on 17 March 2023 at the JW Marriott Grosvenor House London when the industry came together to celebrate the best creative communications in pharma and healthcare. PM Society Co-Chair Caroline Benson kicked off the afternoon, with charity Duchenne UK ...
PME - Magazine Issues
Oct 16, 2024 · PME – Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts.
Enzyvant and Altavant announce merger to accelerate rare disease ...
Dec 8, 2022 · Enzyvant Therapeutics (Enzyvant) and Altavant Sciences (Altavant) have announced a merger to form a biopharmaceutical company focused on accelerating the development of therapies for patients with rare diseases. The combined company, which retains the name Enzyvant, will have a full range of capabilities required to advance ‘bold science ...